Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Oncology

1 Growth Stock Under $100 to Buy Before It Soars

This biotech under $100 looks like a growth opportunity worth grabbing before it soars.

Barchart

Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial

Kura Oncology, Inc. (NASDAQ:KURA) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Kirin.

Benzinga

Whitehawk Therapeutics Stock Is Trading Higher Thursday: What's Going On?

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI Inc (NASDAQ:TEM) to support the development of its oncology pipeline.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations

Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (ex20ins) or uncommon non-ex20ins EGFR mutations.

Benzinga

Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients

Moderna Inc. (NASDAQ:MRNA) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma will be presented at the 2025 European Society for Medical Oncology Congress.

Benzinga

Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug

Zenas BioPharma Inc. (NASDAQ:ZBIO) and InnoCare Pharma Ltd. on Wednesday announced a license agreement granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology.

Benzinga

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. (NASDAQ:CRDF) on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in…

Benzinga

Cardiff Oncology Shares Slide Over 26% In Premarket Trading After Mixed Q2

Following a disappointing second-quarter earnings report, Cardiff Oncology Inc. (NASDAQ:CRDF) experienced a 26.28% drop in its stock value during pre-market trading on Wednesday after reporting mixed Q2 earnings.

Benzinga

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.

Benzinga

Cancer drug demand drives higher sales for AstraZeneca

Revenues from oncology products made up 43% of the company’s total sales.

Evening Standard

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts position them for standout growth in the cancer treatment market.

Barchart

Experts call for end to ‘postcode lottery’ in certain cancer services

Health bodies have called for investment in these ‘essential components of cancer care’ so they do not become ‘optional extras’,

Evening Standard

Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

The Future of Cancer Treatment Is Here — And It Starts with the Right Clinical Trial

Cancer research no longer moves slowly; it advances rapidly. Revolutionary discoveries in precision medicine, immunotherapy, and gene editing emerge almost weekly, yet many patients still confront enormous hurdles when they look for cutting‑edge options.

The Guardian - AU

Sweaty and flustered, my breast cancer patient was experiencing hot flushes. The lack of good treatment is frustrating

Anti-oestrogen medication is the penicillin of oncology, but not enough attention is paid to the living horror that many patients experience as a side-effect

The Independent UK

Leading risk factor for cancer revealed – and it’s not smoking, alcohol or the sun

The factor most associated with cancer is unavoidable, and a condition that we will all experience

International Business Times

Anna Forsythe Built Oncoscope to Give Doctors What They Actually Need: Usable Intelligence

Nowhere is this more critical than in oncology, where every day and every decision can change the course of a patient's life. Anna Forsythe, founder of Oncoscope-AI, an AI-powered oncology intelligence platform, has spent her career at the intersection of science, economics, and clinical practice.

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

The leading risk factor for cancer isn’t what you think

If you were to ask most people what causes cancer, the answer would probably be smoking, alcohol, the sun, hair dye or some other avoidable element. But the most important risk factor for cancer is something else: aging. That’s right, the factor most associated with cancer is unavoidable — and…

International Business Times

Saudi Arabia Advances Cancer Care with Potential Approval of Multikine Immunotherapy

The US-based biotech company has submitted an application to the Saudi Food and Drug Authority (SFDA) for Breakthrough Medicine Designation, a fast-track regulatory pathway that could make Multikine available to patients as early as this summer.

Barchart

Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

International Business Times

Saudi Arabia Advances Cancer Care with Potential Approval of Multikine Immunotherapy

AAP

Hidden crisis in gynaecological cancers affecting women

As 19 women are diagnosed with a gynaecological cancer every day, advocates are calling for more funding to improve treatments after decades of underinvestment.

The Independent UK

My mother was told her tumour was benign – five years later she died

Chloe Hickman is campaigning to make it mandatory to have oncology scans checked by two experts

Barchart

Gilead Sciences - Leader in HIV Medicines

Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline....

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.